Go Deep
Liminatus Pharma, Inc.
Liminatus Pharma, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 13,004 | -0.1 | 14.34 | 4.80 | 304.03 |
| Oct 2026 | 13,390 | -0.1 | 13.58 | 4.80 | 287.93 |
| Oct 2026 | 11,431 | -0.1 | 13.90 | 4.80 | 294.88 |
| Oct 2026 | 11,181 | -0.1 | 14.39 | 4.80 | 305.31 |
| Oct 2026 | 11,408 | -0.1 | 13.94 | 4.80 | 295.10 |
| Oct 2026 | 11,431 | -0.1 | 13.90 | 4.80 | 293.56 |
Liminatus Pharma, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -1,407,259.0 | -1,123,714.0 | -8,168,927.0 | -1,823,351.0 |
| EPS | -0.0 | -0.0 | — | -0.1 |
Liminatus Pharma, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -10,206,517.0 | -3,546,309.0 | -4,984,000.0 | -2,928,000.0 |
| EPS | -0.4 | -0.1 | -0.2 | -0.1 |
Liminatus Pharma, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Total Assets | 512,795.0 | 5,408,859.0 | 2,242,000.0 | 6,843,000.0 |
| Total Liabilities | 10,327,485.0 | 24,748,922.0 | 18,036,000.0 | 17,653,000.0 |
| Total Equity | -9,814,690.0 | -19,340,063.0 | 0.0 | 0.0 |
Owes vs Owns
Liminatus Pharma, Inc. owed $0.91 for every $1 it owned in Jun 2026, down from $2.58 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.91× | 20.1× | 4.58× | 8.04× | 2.58× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Liminatus Pharma, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 65.8%Fixed assets (tangible) 2.4%Other assets 31.8%
How it's funded — Dec 2025
Short-term debt 14.0%Payables 5.6%Other liabilities 80.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 0.3 | 0.1 | 0.4 | 5.0 |
| Receivables | 0.0 | 3.7 | 0.9 | 0.1 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.0 | 0.0 | 0.0 | 0.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 0.2 | 1.7 | 0.9 | 1.7 |
| Liabilities & equity | ||||
| Short-term debt | 1.4 | 20.0 | 16.1 | 16.5 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 0.6 | 1.5 | 0.9 | 0.5 |
| Other liabilities | 8.3 | 3.3 | 1.1 | 0.6 |
| Shareholders' equity | -9.8 | -19.3 | -15.8 | -10.8 |
| Net tangible assets | -9.8 | -19.3 | 0.0 | 0.0 |
Liminatus Pharma, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Operating Activities | -9,963,318.0 | -1,451,066.0 | -3,345,000.0 | -869,000.0 |
| Investing Activities | -788,108.0 | -2,850,000.0 | -819,000.0 | 0.0 |
| Financing Activities | 11,032,762.0 | 3,923,000.0 | -450,000.0 | 5,917,000.0 |